Skip to content

Does in-bed cycling, started within the first 2 days of an admission to ICU, reduce delirium in adults receiving mechanical ventilation?

Does in-bed Cycling delivered within 48 hours of mechanical ventilation, rEduce the occurrence of Delirium in critically ill patients (FRECycl-D): a mixed-methods feasibility randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN74277350
Enrollment
84
Registered
2024-05-23
Start date
2024-07-30
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium in critically ill patients Mental and Behavioural Disorders

Interventions

Participants will be stratified to site and randomised 1:1 using permuted block randomisation to receive either early (within =48 hours following invasive mechanical ventilation) in-bed cycling in add

Sponsors

University Hospitals Plymouth NHS Trust
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1. Adults (aged 18 years and above) 2. Unplanned ICU admissions 3. MV initiated within =48 hours of ICU admission 4. Expected to remain on MV >72 hours

Exclusion criteria

Exclusion criteria: 1. Contra-indications to mobilisation 2. Known or suspected cognitive impairment and/or learning difficulties 3. Plan is for palliation/withdrawal of treatment 4. Immobile prior to ICU admission 5. Body weight over the device safety limit (=135 kg) 6. BMI <18.5 kg/m2 7. Planned ICU admission 8. Pregnancy 9. Prisoners

Design outcomes

Primary

MeasureTime frame
Feasibility and acceptability of early (within =48 hours following invasive mechanical ventilation) in-bed cycling to reduce ICU delirium in mechanically ventilated patients. The following measures will be collected to determine trial feasibility: 1. Recruitment rate (% of participants enrolled vs participants eligible) 2. Retention rate (% of enrolled participants who completed the intervention protocol in full excluding deaths) 3. Intervention fidelity (% intervention sessions completed) 4. The acceptability of the intervention will be evaluated by the key stakeholders (assessed by qualitative interviews) There will be no interim analysis therefore these measures will be collected up until the end of the study period. The end of the study period is defined as the date of the last follow-up visit of the last participant undergoing the study (via telephone or in-person).

Secondary

MeasureTime frame
1. Occurrence of ICU delirium measured using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) on days 0-14 and up to day 30 2. Delirium-free days (CAM-ICU) day-0-14, and up to day 30 3. Duration (days) of ICU-Delirium (CAM-ICU) days 0-14, and up to day 30 4. Severity of ICU-Delirium using the Confusion Assessment Method for the Intensive Care Unit 7 (CAM-ICU-7), delirium severity scale on days 0-14 5. Physical function measured using the Functional Status Score for the Intensive Care Unit (FSS-ICU) on day-14 or out-of-bed mobilisation (whichever comes first) 6. Quality of life measured using the EQ-5D-5L questionnaire and the SF-36 questionnaire at day 90. The quality of life of participants will also be measured from the perspective of their relative or carer using the proxy EQ-5D-5L questionnaire at day 90. 7. Pain measured using the SF-36 questionnaire at day 90 8. Cognition after ICU discharge assessed using the Montreal Cognitive Assessment (MoCA) on day 90 9. Presence of delirium after ICU discharge measured using the Family Confusion Assessment Method (FAM-CAM) at day 90 10. Time to delirium resolution (days) measured using time from delirium diagnosis to time delirium resolved in days/ patient health records 11. ICU and hospital length of stay (days) measured using days of ICU admission to discharge and days of hospital admission to discharge/patient electronic health records 12. Ventilator-free days (days) on days 0-30 measured using days spontaneously breathing i.e., nil invasive ventilator support required between day 0 and day 30 from randomisation/patient electronic health records 13. Sedation-free days (days) on days 0-30 measured using days nil sedation administered between day 0 and day 30 from randomisation/patient electronic health records 14. [Severity of sedation] measured using the Daily Richmond Agitation Sedation Scale (RASS) at day 0 to day 14 from randomisation or out-of-bed mobilisation commences (whichever comes firs

Countries

England, United Kingdom

Contacts

Public ContactJacqueline Bennion
Jacqueline.Bennion@nhs.net+44 (0)1752437333

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 7, 2026